Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments

  • Technology appraisal guidance
  • TA948
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Committee meetings

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators